Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Not applicable Interventional Results available

A Risky Sex Prevention Intervention for Middle School Age Minority Girls

NCT02103218
View directory record Official record
Conditions
HIV, Risky Sex Prevention
Interventions
Education, activities, empowerment, racial pride building, General Health education, activities
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
11 Years to 99 Years · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

NCT01152918
View directory record Official record
Conditions
HIV Infection
Interventions
Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
Not listed
Enrollment
18,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of JULUCA in Hemodialysis

NCT04431518
View directory record Official record
Conditions
HIV/AIDS, ESRD
Interventions
JULUCA 50Mg-25Mg Tablet
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Therapy to Elevate CD4 Counts in HIV-1 Disease

NCT01370018
View directory record Official record
Conditions
HIV Disease
Interventions
alpha-1-Proteinase Inhibitor
Biological
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prison Connect-STI/HIV Prevention Intervention for Couples Affected by Incarceration

NCT03025191
View directory record Official record
Conditions
Incarceration
Interventions
Speaker/Listener technique, Social Support, Problem-Solving, Goal Setting
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 21, 2026, 9:06 AM EDT
Not listed Not applicable Interventional

Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care

NCT01505660
View directory record Official record
Conditions
HIV
Interventions
Care management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Health Problems Associated With Injection Drug Use

NCT01128920
View directory record Official record
Conditions
Intravenous Drug Abuse, HIV Infections
Interventions
Skin and Needle Hygiene Intervention, No intervention - assessment-only condition
Behavioral · Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

NCT00000813
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV gp160MN (vCP125), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Maternal HIV: Trial to Assist Disclosure to Children

NCT01922206
View directory record Official record
Conditions
HIV
Interventions
TRACK Intervention
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
Not listed
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI Testing

NCT03138135
View directory record Official record
Conditions
HIV Prevention, Sexually Transmitted Diseases, Pre-Exposure Prophylaxis
Interventions
HOME Study intervention, Control
Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional

Human Immunodeficiency Virus (HIV) Food Insecurities

NCT04943861
View directory record Official record
Conditions
Food Insecurities, Cardiometabolic Comorbidities, HIV, PreDiabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions
weCare/Secure, Usual Care
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 9:06 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

NCT04551573
View directory record Official record
Conditions
Tuberculosis, Hiv
Interventions
Rifapentine daily, Rifapentine weekly
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

NCT04137094
View directory record Official record
Conditions
Hiv, Hepatitis C
Interventions
Persuasive Health Communication Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting

NCT02037594
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Sexual Health Counseling, Enhanced Adherence Intervention, PrEP Information (Active Control), Standard of Care Adherence Support (Active Control)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection

NCT00002290
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional

Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)

NCT01359280
View directory record Official record
Conditions
Medication Adherence
Interventions
Adherence Counseling, General Health Counseling, Text Messages
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002227
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Brookline, Massachusetts • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120
View directory record Official record
Conditions
Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions
TFV/LNG IVR, Placebo
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PrEPared and Strong: Clinic-Based PrEP for Black MSM

NCT02167386
View directory record Official record
Conditions
HIV/AIDS
Interventions
Enhanced PrEP Adherence, Standard PrEP Adherence
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Growth Hormone to Increase Immune Function in People With HIV

NCT00071240
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin (recombinant human growth hormone)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Oct 21, 2026, 9:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 9:06 AM EDT